Gilles D. Tamagnan, PhD, received his doctorate in medicinal chemistry at the University Joseph Fourier in Grenoble, France in 1993. After a postdoctoral fellowship spent on the crystallization of protein, Dr. Tamagnan completed a second postdoctoral fellowship at RBI in Boston, Massachusetts. His research subject was to develop new ligands for the diagnosis of Parkinson’s disease using compounds labeled with radioactive atoms, and Dr. Tamagnan is a co-inventor of DatScan.
He joined the Neuroimaging Program at Yale University in June 1997 to work on the development of new radioligands to study neurodegenerative diseases and went to the Institute for Neurodegenerative Disorders (IND) in 2003. Dr. Tamagnan has been the recipient of numerous grants and is the co-inventor of ligands used for the diagnosis of Parkinson’s. He joined IND as laboratory research and development director in 2003.